HORIZON THERAPEUTICS USA, INC. (FKA HORIZON PHARMA USA, INC.) for HORIZON THERAPEUTICS USA, INC. (FKA HORIZON PHARMA USA, INC.)
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Taxation/Internal Revenue Code TAX
Issues related to the implementation of PL 115-97 (2017) "Tax Cuts and Jobs Act, all provisions.
Foreign entity interest: Horizon Therapeutics USA, Inc. (FKA Horizon Pharma USA, Inc.) is a US domestic subsidiary of a foreign parent. All lobbying efforts, while not controlled, supervised, or directed by the parent, benefit the parent tangentially.
Health Issues HCR
Issues pertaining to drug pricing and reimbursement, transparency and patient access. S 652 / HR 2620 "Safe Step Act," all provisions. Issues pertaining to the implementation of PL 97-414 "Orphan Drug Act," all provisions. Issues pertaining to improved oversight regulatory requirements for 340B hospital reporting, excluding Federal Grantees. HR 5376 "Inflation Reduction Act," all provisions relating to prescription drug pricing and taxes. HR 3173 "Improving Seniors' Timely Access to Care Act," all provisions. HR 830 "HELP Ensure Copays Act," all provisions.
Foreign entity interest: Horizon Therapeutics USA, Inc. (FKA Horizon Pharma USA, Inc.) is a US domestic subsidiary of a foreign parent. All lobbying efforts, while not controlled, supervised, or directed by the parent, benefit the parent tangentially.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JORDAN CHAPMAN | — |
| ELI KOGAN | — |
| MATT MCMURRAY | — |
| BETH RADA | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.